公开(公告)号：US20190002479A1

公开(公告)日：2019-01-03

申请号：US16023422

申请日：2018-06-29

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： In Jong Kim ,  Jianming yu ,  Joseph Panarese ,  Kevin McGrath ,  Solymar Negretti-Emmanuelli ,  Thomas P. Blaisdell ,  Brian C. Shook ,  Yat Sun Or

IPC: C07D519/00 ,  A61P31/16

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20190002478A1

公开(公告)日：2019-01-03

申请号：US16023363

申请日：2018-06-29

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： In Jong Kim ,  Joseph Panarese ,  Thomas P. Blaisdell ,  Jianming Yu ,  Brian C. Shook ,  Yat Sun Or

IPC: C07D519/00 ,  A61P31/16

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20180258102A1

公开(公告)日：2018-09-13

申请号：US15914016

申请日：2018-03-07

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Brian C. Shook ,  In Jong Kim ,  Thomas P. Blaisdell ,  Jianming Yu ,  Joseph Panarese ,  Yat Sun Or

IPC: C07D513/04 ,  A61K45/06 ,  C07D498/08 ,  C07D495/04 ,  C07D491/048 ,  C07D471/08 ,  A61K31/58 ,  A61K31/56 ,  C07D417/14 ,  A61K31/5513 ,  C07D243/16 ,  C07D413/12 ,  C07D413/14

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US09957281B2

公开(公告)日：2018-05-01

申请号：US15216119

申请日：2016-07-21

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Brian C. Shook ,  In Jong Kim ,  Thomas P. Blaisdell ,  Jianming Yu ,  Joseph Panarese ,  Yat Sun Or

IPC: C07D243/24 ,  C07D403/12 ,  C07D513/04 ,  A61K31/5513 ,  A61K45/06 ,  C07D243/16 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D491/048 ,  C07D495/04 ,  C07D498/08 ,  A61K31/56 ,  A61K31/58

CPC classification number: C07D513/04 ,  A61K31/5513 ,  A61K31/56 ,  A61K31/58 ,  A61K45/06 ,  C07D243/16 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D491/048 ,  C07D495/04 ,  C07D498/08 ,  A61K2300/00

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20170022221A1

公开(公告)日：2017-01-26

申请号：US15216119

申请日：2016-07-21

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Brian C. Shook ,  In Jong Kim ,  Thomas P. Blaisdell ,  Jianming Yu ,  Joseph Panarese ,  Yat Sun Or

IPC: C07D513/04 ,  A61K31/5513 ,  A61K45/06 ,  C07D413/14 ,  C07D471/08 ,  C07D495/04 ,  C07D243/16 ,  C07D498/08 ,  C07D491/048 ,  C07D413/12 ,  C07D417/14

CPC classification number: C07D513/04 ,  A61K31/5513 ,  A61K31/56 ,  A61K31/58 ,  A61K45/06 ,  C07D243/16 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D491/048 ,  C07D495/04 ,  C07D498/08 ,  A61K2300/00

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract translation: 其抑制呼吸道合胞病毒（RSV）。 本发明还涉及药物组合物，其包含用于给患有RSV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者RSV感染的方法。

公开(公告)号：US09242974B2

公开(公告)日：2016-01-26

申请号：US14019604

申请日：2013-09-06

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoyou Xu ,  Datong Tang ,  In Jong Kim ,  Ly Tam Phan ,  Yat Sun Or ,  Zhe Wang

IPC: C07D417/04 ,  C07D417/14 ,  C07D493/08

CPC classification number: C07D417/04 ,  C07D417/14 ,  C07D493/08

Abstract: The present invention relates to processes and intermediates for the preparation of 2-fluoro 6-11 bicyclic erythromycin derivatives. In particular, the present invention relates to processes and intermediates for the preparation of a compound of formula (X-c):

Abstract translation: 本发明涉及制备2-氟6-11双环红霉素衍生物的方法和中间体。 特别地，本发明涉及制备式（X-c）化合物的方法和中间体：

公开(公告)号：US08906853B2

公开(公告)日：2014-12-09

申请号：US14092171

申请日：2013-11-27

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  In Jong Kim ,  Jiang Long ,  Lijuan Jiang ,  Sheng Sean Liu ,  Guoqiang Wang

IPC: A61K38/21 ,  A61K31/7056 ,  A61K45/06 ,  C07K7/64 ,  A61K31/713

CPC classification number: C07K7/645 ,  A61K31/7056 ,  A61K31/713 ,  A61K38/21 ,  A61K45/06 ,  C07K7/64 ,  Y02A50/463 ,  A61K2300/00 ,  A61K38/13

Abstract: The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.

Abstract translation: 本发明涉及对HCV具有抗病毒活性的新型环孢菌素类似物，可用于治疗HCV感染。 更具体地，本发明涉及新的环孢菌素类似物化合物，含有这些化合物的组合物及其使用方法，以及制备这些化合物的方法。

公开(公告)号：US20140187780A1

公开(公告)日：2014-07-03

申请号：US14139936

申请日：2013-12-24

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： In Jong Kim ,  Tongzhu Liu ,  Jiang Long ,  Guoqiang Wang ,  Yao-Ling Qiu ,  Heejin Kim ,  Yanchun Wang ,  Ly Tam Phan ,  Yat Sun Or

IPC: C07D493/08 ,  C07F9/6558

CPC classification number: C07D493/08 ,  C07F9/65586 ,  C07H17/08

Abstract: The present invention discloses compounds of formula I, II or X, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

Abstract translation: 本发明公开了式I，II或X的化合物或其药学上可接受的盐，酯或前药：其表现出抗菌性质。 本发明还涉及包含上述化合物的药物组合物，用于给予需要抗生素治疗的受试者。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。 本发明还包括制备本发明化合物的方法。